Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Adjuvant Radiotherapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    659 result(s) found for: Adjuvant Radiotherapy. Displaying page 1 of 33.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2019-001711-23 Sponsor Protocol Number: ET19-084 Start Date*: 2020-02-03
    Sponsor Name:Centre Léon Bérard
    Full Title: CICA-RT – Phase III randomized multicenter study evaluating Cicaderma® ointment efficacy versus the current practice of each center for the radiation dermatitis prevention in patients with non-meta...
    Medical condition: Breast adenocarcinoma treated with post-operative radiotherapy Post-operative breast cancer radiotherapy
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-001216-19 Sponsor Protocol Number: Start Date*: 2014-11-13
    Sponsor Name:NHS Greater Glasgow & Clyde [...]
    1. NHS Greater Glasgow & Clyde
    2. University of Glasgow
    Full Title: Short-course radiotherapy plus olaparib for newly diagnosed glioblastoma in patients unsuitable for radical chemoradiation: a randomised phase II clinical trial preceded by a lead-in phase I dose e...
    Medical condition: glioblastoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-004952-13 Sponsor Protocol Number: DART Start Date*: 2020-12-14
    Sponsor Name:University Hospital Ghent
    Full Title: Stereotactic body radiotherapy with or without Darolutamide for OligoRecurrent prostate cancer: a randomized phase II trial (DART)
    Medical condition: - Prostate cancer patients with a biochemical recurrence following primary therapy - Hormone-sensitive - Up to 5 metastases on PSMA PET-CT
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071119 Hormone-dependent prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004777-10 Sponsor Protocol Number: 107240 Start Date*: 2007-03-14
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase I/II study to assess the safety and immunogenicity of recMAGE-A3+AS15 cancer immunotherapeutic given as adjuvant therapy, with or without standard adjuvant chemo(-radio)therapy, to patients...
    Medical condition: Adult patients with pathologically proven MAGE A3-positive Non-Small Cell Lung Cancer in stage IB, II or III.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BE (Prematurely Ended) DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000392-14 Sponsor Protocol Number: 1200.131 Start Date*: 2011-07-27
    Sponsor Name:Boehringer Ingelheim Limited
    Full Title: LUX-Head & Neck 2 A randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary...
    Medical condition: Loco-regionally advanced head and neck squamous cell carcinoma with no evidence of disease after chemo-radiotherapy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Prematurely Ended) BE (Completed) FR (Prematurely Ended) NL (Prematurely Ended) DE (Completed) FI (Prematurely Ended) GR (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) IT (Completed) CZ (Prematurely Ended) DK (Prematurely Ended) PT (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020621-40 Sponsor Protocol Number: OCTO_021 Start Date*: 2010-09-30
    Sponsor Name:The University of Oxford
    Full Title: SONATINA: A Phase II Multi-Centre Randomised Controlled Study of Nelfinavir Addition to Radiotherapy Treatment in Neo-Adjuvant Therapy for Rectal Cancer
    Medical condition: inoperable rectal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005181-30 Sponsor Protocol Number: AFT-05/ABCSG-42/BIG_14-03 Start Date*: 2015-07-09
    Sponsor Name:ABCSG GmbH
    Full Title: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor...
    Medical condition: To determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing) ES (Ongoing) IE (Ongoing) HU (Ongoing) PT (Ongoing) DE (Ongoing) SE (Ongoing) NL (Ongoing) BE (Ongoing) PL (Ongoing) GB (GB - no longer in EU/EEA) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-003177-26 Sponsor Protocol Number: RT2019-13 Start Date*: 2020-02-05
    Sponsor Name:UMCG
    Full Title: Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy
    Medical condition: Patients with biochemical recurrence after primary treatment of prostate cancer presenting with ≤4 metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005697-46 Sponsor Protocol Number: RCT 06 Start Date*: 2007-02-12
    Sponsor Name:SOFAR SPA
    Full Title: Prevention of actinic proctitis by beclomethasone dipropionate. A prospectic,randomised, double blind placebo controlled pilot study
    Medical condition: actinic proctitis
    Disease: Version SOC Term Classification Code Term Level
    6.1 10036783 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001355-76 Sponsor Protocol Number: UCL/13/0291 Start Date*: 2016-05-09
    Sponsor Name:University College London
    Full Title: Phase III randomised trial of immunomodulatory therapy in high risk solitary bone plasmacytoma
    Medical condition: Solitary bone plasmacytoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035484 Plasmacytoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-000074-51 Sponsor Protocol Number: GBG 39 Start Date*: 2005-05-03
    Sponsor Name:GBG Forschungs GmbH
    Full Title: A multicenter phase II study to determine the efficacy of capecitabine as first line monochemotherapy in patients with HER2 negative, medium-risk, metastatic breast cancer
    Medical condition: patients with HER2 negative metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001360-39 Sponsor Protocol Number: SU2C-SARC032 Start Date*: 2019-06-24
    Sponsor Name:SARC
    Full Title: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab with Radiotherapy and Adjuvant Pembrolizumab in Patients with High-Risk, Localized Soft Tissue Sarcoma of the Extremity
    Medical condition: This trial investigates whether neoadjuvant radiotherapy combined with pembrolizumab followed by surgical resection and adjuvant pembrolizumab improves disease-free survival for patients with high-...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024629 Liposarcoma metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041298 Soft tissue sarcomas histology unspecified HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005186-10 Sponsor Protocol Number: EGF105485 Start Date*: 2006-09-12
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjuvant Lapatinib in Women with Early-Stage ErbB2 Overexpressing Breast Cancer
    Medical condition: Women with early-stage ErbB2-overexpressing breast cancer. Eligible women must have had an initial diagnosis of histologically or cytologically confirmed invasive breast cancer (Stage I through St...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10065430 HER-2 positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed) LT (Completed) ES (Completed) BE (Completed) DK (Completed) LV (Completed) GR (Completed) SK (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2023-000183-65 Sponsor Protocol Number: TTCC-2022-01-RADIAN Start Date*: 2023-08-23
    Sponsor Name:Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (TTCC)
    Full Title: Phase Ib/II non-randomized non-comparative two-cohort study of Niraparib and Dostarlimab plus (Chemo)RadIotherapy in Locally-Advanced head and Neck squamous cell carcinoma (RADIAN)
    Medical condition: Locally-Advanced head and Neck squamous cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003101-85 Sponsor Protocol Number: OSAG 101-BSA-05 Start Date*: 2007-05-14
    Sponsor Name:Oncoscience AG
    Full Title: Phase-III study of standard radiotherapy plus concomitant and adjuvant OSAG 101 (Theraloc®) plus Temozolomide vs. standard radiotherapy plus concomitant and adjuvant Temozolomide in patient with ne...
    Medical condition: Glioblastoma multiforme grade IV
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001533-17 Sponsor Protocol Number: EORTC26053-22054 Start Date*: 2007-06-25
    Sponsor Name:EORTC European Organisation for research and treatment of cancer
    Full Title: Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON Intergroup trial.
    Medical condition: anaplastic glioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) FR (Completed) IT (Completed) BE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-003896-35 Sponsor Protocol Number: EORTC 26041_22041 Start Date*: 2005-08-01
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Phase I/II study on concomitant and adjuvant Temozolomide and Radiotherapy with or without PTK787/ZK222584 in newly diagnosed GBM
    Medical condition: Glioblastoma multiforme
    Disease: Version SOC Term Classification Code Term Level
    7.1 10018337 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) AT (Completed) GB (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001471-36 Sponsor Protocol Number: PrimeRT-2018 Start Date*: 2020-10-05
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. The University of Glasgow
    Full Title: Priming the Tumour MicroEnvironment for Effective Treatment with Immunotherapy in Locally Advanced Rectal Cancer: A Phase II trial of Durvulamab in Combination with Extended Neoadjuvant Regimens i...
    Medical condition: Rectal Cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038038 Rectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-004263-35 Sponsor Protocol Number: CFEM345D2411 Start Date*: 2006-03-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomised multi-center Phase IIIb, open label, study of letrozole vs anastrazole in the adjuvant treatment of postmenopausal women with hormone receptor and node positive breast cancer
    Medical condition: This study will be a head to head comparison of letrozole versus anastrozole in the adjuvant treatment of high risk patients. Post-menopausal patients who recently have undergone their primary surg...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Prematurely Ended) FI (Prematurely Ended) ES (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended) AT (Completed) DK (Completed) BE (Completed) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004796-11 Sponsor Protocol Number: CZOL446GDE24 Start Date*: 2007-08-14
    Sponsor Name:Klinikum Augsburg
    Full Title: An Open-Label, Non-Randomized, Single center Study to Evaluate the Use of Zoledronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women with ER+ and/or PgR+ Breast...
    Medical condition: Prevention of cancer treatment-related bone loss in postmenopausal women with resected stage I-IIIa hormone receptor positive breast cancer, who will receive letrozole as adjuvant therapy.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:35:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA